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Brief Definit ive Report
Injury can trigger an acute inflammatory re-
sponse, even in the absence of concomitant 
infection. “Sterile” inflammation is also associ-
ated with several types of cancer. Two events are 
key for the development of sterile inflammation: 
the recruitment of leukocytes, especially neu-
trophils and monocytes, and their activation to 
release proinflammatory cytokines.
High-mobility group box 1 (HMGB1) is a 
nuclear protein that signals tissue damage 
when released into the extracellular medium, 
and thus works as a damage-associated molec-
ular pattern (DAMP; Bianchi, 2007). Extracel-
lular HMGB1 can act both as a chemoattractant 
for leukocytes and as a proinflammatory media-
tor to induce both recruited leukocytes and resi-
dent immune cells to release TNF, IL-1, IL-6, 
and other cytokines. Notably, immune cells se-
crete HMGB1 when activated by infection or 
tissue damage (Andersson and Tracey, 2011); 
mesothelioma and other cancer cells secrete 
HMGB1 constitutively (Jube et al., 2012).
Recent studies have shown that the pro-
inflammatory cytokine-stimulating activity of 
HMGB1 depends on the redox state of three cys-
teines: C23 and C45 must form a disulfide bond 
within the first HMG-box domain of HMGB1, 
BoxA, whereas the unpaired C106 within BoxB 
must be in the thiol state (Yang et al., 2012). 
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Tissue damage causes inflammation, by recruiting leukocytes and activating them to release 
proinflammatory mediators. We show that high-mobility group box 1 protein (HMGB1) 
orchestrates both processes by switching among mutually exclusive redox states. Reduced 
cysteines make HMGB1 a chemoattractant, whereas a disulfide bond makes it a proinflam-
matory cytokine and further cysteine oxidation to sulfonates by reactive oxygen species 
abrogates both activities. We show that leukocyte recruitment and activation can be 
separated. A nonoxidizable HMGB1 mutant in which serines replace all cysteines (3S-HMGB1) 
does not promote cytokine production, but is more effective than wild-type HMGB1 in 
recruiting leukocytes in vivo. BoxA, a HMGB1 inhibitor, interferes with leukocyte recruit-
ment but not with activation. We detected the different redox forms of HMGB1 ex vivo 
within injured muscle. HMGB1 is completely reduced at first and disulfide-bonded later. 
Thus, HMGB1 orchestrates both key events in sterile inflammation, leukocyte recruitment and 
their induction to secrete inflammatory cytokines, by adopting mutually exclusive redox states.
© 2012 Venereau et al This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Figure 1. Characterization of HMGB1 redox states. (A) Mass spectrometric characterization of HMGB1 purified with DTT (top) or without DTT (bot-
tom). Characterization of C23: MS-MS trace of the peptide containing amino acids 13–24, with an iodoacetamide adduct indicating reduced C23 (top) or 
with a NEM adduct after DTT reduction of a disulfide bond (bottom). Characterization of C45: MS-MS trace of the peptide containing amino acids 45–48, 
with an iodoacetamide adduct indicating reduced C45 (top) or with a NEM adduct after DTT reduction of a disulfide bond (bottom). Characterization of 
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modification of cysteines was identified within these forms 
of HMGB1.
The presence of disulfide bonds is often associated with an 
increased electrophoretic mobility in nonreducing conditions, 
which is a result of a more compact folding of the polypeptide 
chain. All-thiol-HMGB1 migrated as a single band with an 
apparent molecular weight of 28 kD, both in reducing and 
nonreducing conditions. In contrast, disulfide-HMGB1 mi-
grated in nonreducing conditions as a single band of 26 kD 
and shifted in reducing conditions to the same 28 kD position 
as all-thiol-HMGB1 (Fig. 1 B). Monoclonal or polyclonal anti-
bodies against HMGB1 recognized both forms of HMGB1 
(Fig. 1 B). Disulfide-HMGB1 was readily shifted to the all-
thiol-HMGB1 electrophoretic pattern after 5-min exposure 
to 5 mM DTT; conversely, we occasionally detected the for-
mation of disulfide-HMGB1 after dilution in air-equilibrated 
buffers lacking reducing agents. This indicates that all-thiol- and 
disulfide-HMGB1 forms are readily interconverted in the pres-
ence of electron donors (DTT) or acceptors (oxygen).
The cytokine-stimulating and chemoattractant  
activities of HMGB1 are mutually exclusive
Recently, Yang et al. (2012) showed that disulfide-HMGB1 
has cytokine-stimulating activity that is lost after reduction 
with DTT. We confirmed that disulfide-HMGB1 induces 
activation of the NF-B pathway (Fig. 1 C) and cytokine/
chemokine expression by macrophages (Fig. 1 D), whereas 
all-thiol-HMGB1 does not. However, the influence of redox 
modifications on the chemotactic activity of HMGB1 was 
not known. We recently showed that HMGB1-induced 
recruitment of inflammatory cells is dependent on the forma-
tion of a HMGB1–CXCL12 heterocomplex that acts exclu-
sively through CXCR4 and not through other HMGB1 
receptors (Schiraldi et al., 2012). Using a hybrid ELISA 
(anti-CXCL12 capture antibody and anti-HMGB1 detection 
antibody), we found that all-thiol-HMGB1 forms the hetero-
complex with CXCL12; no heterocomplex formation could 
be detected between disulfide-HMGB1 and CXCL12 (Fig. 2 A). 
All-thiol-HMGB1 synergizes with CXCL12 in inducing 
human monocyte migration, as expected (Schiraldi et al., 
2012), whereas disulfide-HMGB1 does not (Fig. 2 B).
Fibroblasts, respond to lower concentrations of HMGB1 
compared with leukocytes (Palumbo et al., 2007) and support 
their own migration by secreting CXCL12 both basally and 
in response to HMGB1 activation of the receptor for ad-
vanced glycation end products (RAGE; Schiraldi et al., 2012). 
Both terminal oxidation of these cysteines to sulfonates 
(CySO3–) with reactive oxygen species (ROS) and their 
complete reduction to thiols (CySH) abrogates the cytokine-
stimulating activity.
We now find that only the fully reduced form of HMGB1, 
where all three cysteines are in the thiol state, can recruit 
motile cells. Because the disulfide and thiol states of cysteines 
are mutually exclusive, the cytokine-stimulating and che-
motactic activities of HMGB1 should also be mutually exclu-
sive, which is what we show experimentally. HMGB1 terminally 
oxidized to sulfonates has no activity, either as a chemoattractant 
or in cytokine stimulation. Replacement of all three cysteines 
with serines makes HMGB1 nonoxidizable, thus preventing 
both its cytokine-stimulating activity and its eventual inactivation, 
but preserving the chemoattractant activity.
Our results indicate that mutually exclusive molecular 
forms of HMGB1 orchestrate both of the key events in sterile 
inflammation: leukocyte recruitment and activation of cyto-
kine release.
RESULTS AND DISCUSSION
Recombinant HMGB1 can be reversibly  
oxidized and reduced
All previous studies by our group relied on bacterially pro-
duced full-length HMGB1 protein, which was purified in 
the presence of dithiothreitol (DTT) added to degassed 
buffers (Knapp et al., 2004). Because HMGB1 can exist in 
different redox forms, we compared different batches of 
HMGB1 purified in the presence or absence of DTT. We 
specifically excluded any LPS contamination (see Materials 
and methods). To characterize the redox state of HMGB1, 
we alkylated reduced cysteines with iodoacetamide, and then 
reduced disulfide bonds with DTT and reacted them with 
N-ethylmaleimide (NEM); we then performed tryptic di-
gestion and liquid chromatography tandem mass spectromet-
ric analysis (LC-MS/MS). HMGB1 purified with DTT gave 
rise to peptides of 1,569.1 (doubly charged ion 784.52+), 
622.6 (doubly charged ion 311.32+), and 2,070.0 D (triply 
charged ion 690.03+). MS/MS revealed an iodoacetamide 
adduct on all cysteines, which is indicative of a thiol side 
chain (Fig. 1 A, top); we will henceforth call this form all-
thiol-HMGB1. A similar analysis of HMGB1 produced in 
the absence of DTT revealed NEM adducts on C23 and 
C45, indicating that they formed a disulfide bond (Fig. 1 A, 
bottom). C106 was also reduced in this form of HMGB1 
(henceforth, disulfide-HMGB1). No SOH, SO2H, or SO3H 
C106: MS-MS trace of the peptide containing amino acids 97–112 with an iodoacetamide adduct indicating reduced C106 (top); the MS-MS trace from 
disulfide-HMGB1 was identical and is not depicted. (B) Electrophoretic mobility of recombinant HMGB1 prepared in the presence (+DTT) or absence of 
DTT (DTT). Samples were heated in the presence (+) or absence () of 350 mM -mercaptoethanol (-me), loaded onto a 12% SDS-PA gel, and revealed 
by Coomassie staining (left) or by Western blotting using a mAb or a pAb against HMGB1 (right). (C) Nuclear translocation of p65-GFP (indicated with 
white arrows) was visualized by confocal microscopy in living mouse embryonic fibroblasts exposed for 30 min to 80 nM disulfide- or all-thiol HMGB1. 
Data are representative of three independent experiments. (D) Human macrophages were exposed for 4 h to 0.4 µM of disulfide- or all-thiol-HMGB1.  
The levels of TNF, IL-6, and IL-8 mRNAs were measured by real-time PCR and expressed as fold increase compared with unstimulated macrophages 
(*, P < 0.05, Student’s t test). Error bars represent standard deviation. Data are representative of three experiments performed with macrophages from 
unrelated healthy individuals.
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and cytokine-stimulating functions of HMGB1 require differ-
ent receptors: CXCR4 and Toll-like receptor 4, respectively 
(Yang et al., 2010; Schiraldi et al., 2012). The small conforma-
tional rearrangements associated with the formation of a single 
disulfide bond decreased, but did not abrogate, the binding of 
HMGB1 to DNA (Park and Lippard, 2011); how they can 
segregate and restrict so effectively the interactions of the all-
thiol- and disulfide-HMGB1 to CXCL12 and Toll-like recep-
tor 4, respectively, still needs to be investigated.
ROS abrogate the proinflammatory activity of HMGB1 
by terminally oxidizing its cysteines to sulfonates (Kazama 
Mouse 3T3 fibroblasts migrated in a dose-dependent manner 
toward all-thiol-HMGB1, but not toward disulfide-HMGB1 
(Fig. 2 C). Notably, the addition of DTT to disulfide-HMGB1 
(newly all-thiol HMGB1) restored almost completely the 
chemotactic activity of the protein.
Collectively, our results indicate that the formation of the 
C23-C45 disulfide bond inhibits the chemoattractant func-
tion of HMGB1 (Fig. S1). Thus, the cytokine-stimulating and 
chemoattractant activities of HMGB1 are mutually exclusive. 
In addition, disulfide-HMGB1 and all-thiol-HMGB1 do not 
compete with each other (Fig. 2 D). Indeed, the chemoattractant 
Figure 2. The cytokine-stimulating and chemoattractant activities of HMGB1 are mutually exclusive. (A) HMGB1/CXCL12 heterocomplex  
detected by hybrid ELISA. All-thiol- or disulfide-HMGB1 (7.5 ng) were preincubated with the indicated amount CXCL12 at 37°C for 15 min. The formation 
of the heterocomplex was detected by hybrid ELISA (an anti-CXCL12 capture antibody and an anti-HMGB1 detection antibody). Results are expressed as 
absorbance at 450 nm (*, P < 0.05, ANOVA). (B) Human monocyte migration in response to increasing concentrations of CXCL12 in the presence or 
absence of 300 nM all-thiol- or disulfide-HMGB1 (*, P < 0.01 vs. CXCL12 alone; 2-way ANOVA). (C) Migration of mouse 3T3 fibroblasts toward disulfide-
HMGB1 or all-thiol-HMGB1, or disufide-HMGB1 exposed to 5 mM of DTT for 30 min (newly all-thiol-HMGB1; *, P < 0.05 vs. disulfide-HMGB1, ANOVA). 
(D) Migration of 3T3 fibroblasts toward all-thiol-HMGB1 in the presence of increasing concentrations of disulfide-HMGB1, and expression of TNF (as fold 
increase compared with unstimulated macrophages) in human macrophages stimulated for 4 h with disulfide-HMGB1 in the presence of increasing con-
centrations of all-thiol-HMGB1. The effects of the competing form of HMGB1 are not statistically significant (ANOVA). (E and F) Migration of mouse 3T3 
fibroblasts toward WT all-thiol-HMGB1 previously exposed to increasing concentrations of H2O2 for 1 h (E; *, P < 0.05 vs. all-thiol HMGB1 not treated 
with H2O2, ANOVA), and toward WT all-thiol-HMGB1 or the E106 mutant purified in the presence of DTT (F; *, P < 0.05 vs. untreated control). (G) Human 
macrophages were stimulated for 4 h with WT disulfide-HMGB1 or the E106 mutant (0.4 µM) prepared in the absence of DTT. Expression of TNF, MIP-2, 
and IL-8 was measured by real-time PCR and expressed as fold increase compared with unstimulated macrophages (*, P < 0.05 vs. disulfide-HMGB1;  
Student’s t test). In all panels, data are representative of at least three independent experiments and bars represent the mean ± SD of triplicate samples 
(when not visible, they fall within symbols).
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in response to HMGB1, but failed to prevent HMGB1-
 induced TNF expression in macrophages (Fig. 3, A and B). 
We also tested the activity of the monoclonal antibody DPH1.1, 
directed against an epitope between BoxB and the acidic tail 
of HMGB1 (Sitia et al., 2011). We prepared F(ab’)2 frag-
ments to avoid the unspecific activation of macrophages: 
they inhibit HMGB1-induced cell migration but not TNF 
expression (Fig. 3, C and D). Previous studies have demon-
strated that a different anti-HMGB1 monoclonal antibody 
(2G7) inhibits HMGB1-induced cytokine formation in macro-
phages (Yang et al., 2010).
Thus, it is possible to neutralize the chemoattractant 
activity of HMGB1 without interfering with the cyto-
kine-inducing activity. In fact, the known therapeutic effects 
of BoxA in models of hepatitis (Sitia et al., 2007), perito-
nitis (Orlova et al., 2007), ischemia/reperfusion of the heart 
and the brain (Andrassy et al., 2008; Muhammad et al., 
2008), and other ailments, may be entirely attributable 
to the reduced recruitment of inflammatory cells in the 
injured tissue.
The three HMGB1 cysteine residues are required  
for the cytokine-stimulating activity  
but not for the chemoattractant activity
To study the involvement of individual cysteines in the 
activities of HMGB1, we generated mutants 1S-HMGB1 
(where C106 is replaced by a serine), 2S-HMGB1 (where 
C23 and C45 are replaced), and 3S-HMGB1 (where all three 
cysteines are replaced). All mutants were purified without 
DTT, and were reduced where indicated by exposure to 
5 mM DTT. Electrophoretic mobility showed the presence 
of the C23-C45 disulfide bond in 1S-HMGB1, but not in 
2S-HMGB1 and 3S-HMGB1 (Fig. 4 A). All mutants failed 
to induce TNF expression in macrophages, but they all 
induced fibroblast migration (Fig. 4, B and C). As expected, 
2S- and 3S-HMGB1 had the same 
chemotactic activity whether ex-
posed to DTT or not, as there is no 
et al., 2008; Yang et al., 2012). We show that HMGB1 exposed 
to H2O2 has no chemotactic activity (Fig. 2 E). Thus, terminal 
oxidation makes HMGB1 inactive, both as proinflammatory 
and chemotactic factor (Fig. S1). To mimic irreversible 
oxidation to sulfonate, C106 was replaced by a glutamic acid. 
The electrophoretic mobility of mutant E106 in reducing 
and nonreducing conditions was identical to that of WT 
HMGB1 (unpublished data). Whereas WT all-thiol-HMGB1 
has optimal chemotactic activity on fibroblasts at 1 nM, the 
E106 mutant, whether exposed to DTT or not, was ineffective 
up to 3 nM (Fig. 2 F). It also failed to induce cytokine/
chemokine expression by macrophages (Fig. 2 G). More-
over, the E106 mutant cannot compete with WT all-thiol- and 
disulfide-HMGB1 in migration and inflammation assays, 
respectively (unpublished data), suggesting that the E106 
mutant cannot bind to HMGB1 receptors.
Overall, our results demonstrate that the activities of 
HMGB1 are redox-dependent. After the original description of 
HMGB1-induced cytokine release by macrophages (Andersson 
et al., 2000), several studies could not reproduce these re-
sults, leading us to conclude that HMGB1 can only act in 
synergy with other inflammatory mediators (Bianchi, 2009). 
Our study differs in that we conclude that inconsistent results 
were obtained by using inconsistently defined forms of 
HMGB1. To understand pathogenesis, it will be important 
to consider which HMGB1 is present in each specific condi-
tion and locale in vivo.
HMGB1 inhibitors BoxA and monoclonal antibody DPH1.1 
prevent cell migration but not cytokine production
Several inhibitors of HMGB1 have been developed, among 
which the most commonly used are monoclonal antibodies 
and BoxA. We investigated whether they block HMGB1’s 
chemoattractant and/or cytokine-inducing activities. BoxA in-
hibited in a dose-dependent manner the migration of fibroblasts 
Figure 3. BoxA and monoclonal antibody 
DPH1.1 prevent HMGB1-induced cell  
migration but not cytokine expression.  
(A and C) Migration of mouse 3T3 fibroblasts 
toward WT all-thiol-HMGB1 in the presence 
or not of BoxA (A) or F(ab’)2 fragments from the 
DPH1.1 anti-HMGB1 monoclonal antibody (C). 
(B and D) Human macrophages were stimu-
lated for 4 h with disulfide-HMGB1 (0.4 µM) 
in the presence of BoxA (B) or DPH1.1 F(ab’)2 
fragments (D). Expression of TNF was mea-
sured by real-time PCR and expressed  
as fold increase compared with unstimulated 
macrophages. In all panels, data are repre-
sentative of at least three independent  
experiments and bars represent the mean ± SD 
of triplicate samples (*, P < 0.05 vs.  
control; ANOVA). 
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We next investigated the redox state of HMGB1 in vivo 
during muscle injury and the subsequent sterile inflamma-
tion, using electrophoretic mobility as an assay. Tibialis ante-
rior muscles of mice were damaged or not by cardiotoxin 
(CTX) injection, which causes muscle cell necrosis (Ownby 
et al., 1993). Muscles were harvested 2, 6, 24, or 72 h after 
CTX injection and incubated in PBS with Collagenase D 
(Fig. 5 A). HMGB1 was barely detectable in the medium bath-
ing healthy muscles, but was abundant in the medium bathing 
CTX-injured muscles. At early time points (2 h) all-thiol-
HMGB1 was detected, but after 6 h disulfide-HMGB1 ap-
peared. It is possible that infiltrating inflammatory cells secrete 
disulfide-containing HMGB1, as we observed in vitro with 
monocytic cells (Fig. S2). Indeed, leukocytes are recruited 
into damaged muscle already by 3 h after CTX injection 
(Schiraldi et al., 2012). A nonmutually exclusive explana-
tion is that the infiltrating cells, a well-known source of 
ROS, may induce the oxidation of HMGB1 released by 
the damaged tissue. Moreover, disulfide-HMGB1 is not pres-
ent in the healthy muscle as demonstrated by the lysate con-
trol. Thus, disulfide-HMGB1 can be considered as a marker 
of tissue damage.
Because 3S-HMGB1 is resistant to oxidation, we hypoth-
esized that its activity in vivo should not be modified by ROS 
production. We previously showed (Schiraldi et al., 2012) that 
the HMGB1–CXCL12 heterocomplex induces a massive in-
flux of leukocytes into air pouches created by the injection of 
air in the dorsal derma of mice; such air pouches provide a 
cavity into which drugs can be administered and from which 
recruited cells can be recovered. We injected into air-pouches 
WT or 3S-HMGB1 (300 pmol) together with CXCL12 
(10 pmol). HMGB1 (WT or 3S) or CXCL12 alone failed to 
induce leukocyte recruitment, but both WT and 3S-HMGB1 
in association with CXCL12 induced a massive influx of 
leukocytes (Fig. 5 B). Notably, the number of recruited leuko-
cytes was increased in response to 3S-HMGB1–CXCL12 
compared with WT HMGB1–CXCL12. Because a low 
amount of CXCL12 is always pres-
ent in the extracellular fluids, and 
HMGB1 can induce the secretion of 
disulfide bond that can be reduced. Thus, all cysteines are re-
quired for the cytokine-stimulating activity, but none for the 
chemoattractant activity of HMGB1.
We next investigated if the chemotactic activity of the 
mutants was abrogated by ROS. As expected, treatment with 
H2O2 abrogated the chemotactic activity of 1S- and 2S-
HMGB1, but not of 3S-HMGB1, which has no cysteine that 
can be terminally oxidized (Fig. 4 D).
Cysteine oxidation modulates the different  
functions of HMGB1 in vivo
Many studies have shown that during inflammation, ROS 
production supports an extracellular oxidative environment, 
causing the formation of disulfide bonds between thiols 
(Carta et al., 2009; Rubartelli and Sitia, 2009). High ROS 
levels produced during apoptosis cause terminal oxidation 
of HMGB1, redirecting its ability to activate acquired immune 
responses toward tolerance (Kazama et al., 2008). A previous 
study suggested that HMGB1 released by necrotic cells also 
gets oxidized (Urbonaviciute et al., 2009). Finally, HMGB1 
has been shown to be a redox sensor in the context of 
autophagy (Kang et al., 2011). Thus, we investigated whether 
the redox state of HMGB1 depends on its source.
HMGB1 is released passively into the extracellular medium 
during necrosis and is secreted actively by monocytes and 
macrophages after stimulation with LPS and ATP (Gardella 
et al., 2002). We characterized by LC-MS/MS the redox 
state of HMGB1 before and after release by THP-1 cells 
(Fig. S2). The HMGB1 contained inside the cell (nucleus 
or cytosol) is completely reduced, also when THP-1 cells are 
exposed to LPS. Notably, the supernatants from THP-1 cells 
mechanically necrotized with freeze–thaw cycles or from 
cells secreting HMGB1 after LPS exposure contained both 
all-thiol- and disulfide-HMGB1. Thus, we identified mono-
cytic cells as a source of disulfide-HMGB1. Activated monocytes 
may participate in the inflammatory response by producing the 
cytokine-stimulating HMGB1.
Figure 4. HMGB1 cysteines are essential 
to promote cytokine/chemokine produc-
tion, but not for chemotaxis. (A) Electro-
phoretic mobility of recombinant WT HMGB1 
and mutants prepared in the absence of DTT, 
determined as described in the legend of Fig. 1 B. 
(B) Human macrophages were stimulated 
for 4 h with mutants or WT HMGB1 prepared 
in the absence of DTT (0.4 µM). TNF expression 
was measured by real-time PCR (*, P < 0.05 
vs. control, ANOVA). (C and D) 3T3 fibroblast 
migration toward 1 nM HMGB1 mutants, 
exposed or not for 1 h to 5 mM DTT (C) or to 
100 mM H2O2 (D). Bars represent the mean ± 
SD of triplicate samples (*, P < 0.05 vs. con-
trol, ANOVA).
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additional CXCL12 (Schiraldi et al., 2012), we also per-
formed the air-pouch experiments using high concentra-
tions of HMGB1 alone. The injection into the air pouch of 
1 nmol 3S-HMGB1 induced leukocyte recruitment, but the 
equivalent amount of all-thiol WT HMGB1 had no effect 
(Fig. 5 C). However, higher doses of all-thiol WT or 3S-
HMGB1 (10 nmol) both recruited leukocytes, with no sig-
nificant difference. This is compatible with stoichiometric 
inactivation of HMGB1 by ROS produced in situ. To con-
firm this hypothesis, we performed the same experiment in 
the presence or not of N-acetylcysteine (NAC), an antioxi-
dant (Fig. 5 D). We observed that 1 nmol WT protein induced 
leukocyte recruitment as effectively as 3S-HMGB1 in the 
presence of NAC, demonstrating that WT HMGB1 gets 
inactivated in vivo by ROS-induced oxidation.
Collectively, in vitro and in vivo experiments show 
that 3S-HMGB1 can induce leukocyte recruitment without 
inducing cytokine/chemokine production and is also resis-
tant to terminal oxidation by ROS. HMGB1 has been shown 
to promote regeneration in several models of tissue damage, 
and all such experiments were performed with the reduced 
form of recombinant WT HMGB1 (Biscetti et al., 2011). 
However, the redox states of HMGB1 administered in vivo 
may interconvert among each other. Future investigations of 
inflammation and tissue regeneration will require the identi-
fication of the HMGB1 redox form involved; for example, 
no studies so far have shown which is the redox state of 
HMGB1 required for neo-angiogenesis, stem cell recruit-
ment, and cell proliferation. 3S-HMGB1 may help solve these 
questions, and may hold promise as a therapeutic intervention 
to favor tissue regeneration.
In conclusion, we show that the DAMP activities of 
HMGB1—recruitment of leukocytes and their activation to 
secrete proinflammatory cytokines—depend on different and 
mutually exclusive redox states of the same polypeptide, 
which can be modified within the injured tissues after its 
release. In the model of muscle injury, all-thiol-HMGB1 is 
prevalent in the extracellular environment immediately after 
damage, and disulfide-HMGB1 appears a few hours later; we 
suggest that all-thiol-HMGB1 is released first to recruit leu-
kocytes, which in turn produce disulfide-HMGB1 directly 
by secretion and/or indirectly by partially oxidizing extra-
cellular HMGB1 with ROS. Finally, sustained ROS produc-
tion eventually induces the terminal oxidation of HMGB1, 
which gets inactivated during the resolution of inflamma-
tion. Because HMGB1 can be readily modified by electron 
Figure 5. Oxidation modulates the activities of HMGB1 in vivo. 
(A) Electrophoretic mobility of HMGB1 from tibialis anterior muscles har-
vested at the indicated times after CTX injection. Samples were heated in 
the presence (+) or absence (–) of 350 mM -mercaptoethanol (-me), 
loaded onto a 12% SDS-PAGE gel and revealed by Western blotting using 
a polyclonal antibody against HMGB1. Total lysate of tibialis anterior 
muscle was added as a control (L). (B–D) 3S-HMGB1 induces leukocyte 
recruitment in vivo. An air pouch was created in mice by the dorsal sub-
cutaneous injection of air. At day 6, the air pouches were injected with 
200 µl of PBS containing 10 pmol CXCL12, 300 pmol HMGB1 (WT or 3S), 
or both. (C) Alternatively, air pouches were injected with 200 µl of PBS 
containing or not containing 1 or 10 nmol HMGB1 (WT or 3S; C) or with  
1 nmol HMGB1 (WT or 3S) in absence or presence of N-acetylcysteine 
(NAC; 100 nmol/g; D). After 6 h, cells were collected from the air pouches, 
stained with anti-Ly6C and anti-CD11b antibodies, and analyzed by flow 
cytometry (WBCs, white blood cells; *, P < 0.05; **, P < 0.01; ***, P < 0.001, 
ANOVA plus Dunnett’s posttest).
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PMSF, 20 mM NaCl (plus 0.5 mM DTT where appropriate), and loaded on 
a Hi-trap Q column (GE Healthcare). Proteins were eluted with an increas-
ing ionic-strength buffer (from 20 mM to 1 M NaCl) in 50 mM Hepes, 
pH 7.9, 0.2 mM PMSF, 1 M NaCl (plus 0.5 mM DTT where appropriate). 
The purity and integrity of purified HMGB1 was verified by Coomassie blue 
staining after SDS-PAGE. We also tested HMGB1 before and after digestion 
with DNase I (100 U/ml, Invitrogen), and we observed no difference in ac-
tivity. The protein was stored at –80°C. Buffers were always degassed before 
use. E106, 1S-, 2S-, and 3S-HMGB1 mutants were generated using the Quik-
Change XL Site-Directed Mutagenesis kit according to the manufacturer’s 
instructions (Stratagene), and were checked by sequencing. Mutant proteins 
were expressed, purified, and quality-controlled as WT HMGB1.
LPS in HMGB1 preparations. Contaminating LPS was removed from 
protein preparations by Triton X-114 extraction (Knapp et al., 2004). We 
measured LPS in HMGB1 samples from all preparations using the Cambrex 
Limulus Amoebocyte Assay QCL-1000 (Lonza) before and after terminal 
digestion with trypsin (therefore excluding any interference of HMGB1 
with the assay). LPS content was always below 0.4 ng/mg protein; this 
amount of LPS is totally ineffective in our assays when administered alone 
(unpublished data). Experiments were also performed in presence of Poly-
myxin B (10 µg/ml) to neutralize the biological activity of LPS, even though 
it was not found in HMGB1 preparations.
Preparation of reduced or terminally oxidized HMGB1. WT or mu-
tants HMGB1 were exposed to either 100 mM H2O2 or 5 mM DTT for 1 h 
and dialyzed before the addition to cells or other analyses.
Mass-spectrometric characterization of the cysteine oxidation sta-
tus of recombinant or circulating HMGB1. Reduced cysteine residues 
within HMGB1, either recombinant or obtained from THP-1 cells, were 
characterized by thiol-specific alkylation with 50 mM iodoacetamide for 30 min. 
Alkylation with iodoacetamide yields a mass-shift of 57 amu (atomic mass 
unit). After the incubation, recombinant HMGB1 preparations were precipi-
tated with ice-cold methanol (MeOH). The pellet was recovered after cen-
trifuging at 14,000 g at 4°C for 10 min. The presence of SOH residues in 
cysteines was investigated with a 20-min incubation with 0.1 mM dimedone 
(5,5-dimethyl-1,3-cyclohexanedione). SO2H and SO3H oxidative modifica-
tions were sought by looking for mass increases of 32 and 48 amu, respec-
tively, on each particular cysteine residue. After the first alkylation step, 
remaining cysteine residues engaged in a disulfide bond were reduced with 
1 mM DTT at 4°C for 15 min. Newly reduced cysteines were then alkylated 
with 50 mM N-ethylmalemide (NEM) for 5 min on ice, which yields a mass 
shift of 125 amu. HMGB1 was isolated by immunoprecipitation from THP-1 
samples, as previously described (Antoine et al., 2009). Proteins were then 
separated by nonreducing SDS-PAGE, and protein bands corresponding to 
the molecular weight of HMGB1 were excised and subjected to tryptic di-
gestion. The resulting peptides were characterized by liquid chromatography 
and tandem mass spectrometry (LC-MS/MS) as described previously 
(Antoine et al., 2009). Individual peptide fragmentation to produce b and 
y ions was used to determine the amino acid sequence and confirm the pres-
ence of specific modifications.
Western blotting. Total protein content in muscle samples from control or 
CTX-treated mice was determined using the Protein Assay Dye Reagent 
(Bio-Rad Laboratories). Equivalent amounts of proteins were loaded on 
gels. For Western blotting, protein samples were separated on 12% SDS-PA 
gels and transferred on nitrocellulose membranes, which were blocked 
with 5% skim milk in Tris-buffered saline, pH 7.0, containing 0.1% 
Tween 20 (TBS-T). Blocked membranes were probed with rabbit anti-
HMGB1 (1:1,000) in TBS-T plus 5% milk overnight at 4°C, washed 
several times with TBS-T, and incubated for 1 h with anti–rabbit peroxidase-
conjugated antibody (1:10,000). Western blots were visualized using an 
enhanced chemiluminescence kit according to the manufacturer’s in-
structions (GE Healthcare).
addition and removal, the limelight shifts onto the cells, the 
molecules, and the biochemical pathways that control elec-
tron flow to HMGB1 both within and outside of the cell.
MATERIALS AND METHODS
Reagents. Human macrophage colony-stimulating-factor (M-CSF) and 
granulocyte macrophage colony-stimulating-factor (GM-CSF) were pur-
chased from R&D Systems. DME, X-Vivo medium, PBS, glutamine and 
penicillin/streptomycin were obtained from Lonza. FBS was obtained from 
Invitrogen, and hydrogen peroxide (30%) was purchased from BDH Chem-
icals Ltd. Polyclonal rabbit anti–human HMGB1 antibody was purchased 
from Abcam, and the monoclonal mouse anti-HMGB1 DPH1.1 antibody 
was from HMGBiotech Srl. F(ab’)2 fragments were generated from the 
DPH1.1 antibody using the mouse IgG1 Fab and F(ab)2 micropreparation 
kit (Thermo Fischer Scientific) after the manufacturer’s instructions. All 
other chemicals and materials were purchased from Sigma-Aldrich.
Mice and treatments. 8-wk-old C57BL/6 mice were purchased from The 
Jackson Laboratory. Sterile injury was induced by injection of 15 µM CTX 
in the tibialis anterior muscle. After the indicated times, muscles were iso-
lated from mice and incubated for 2 h at 37°C in PBS containing protease 
inhibitors and Collagenase D (Roche); samples were centrifuged and super-
natants were preserved at 80°C before Western blotting. Air pouches were 
established in 8-wk-old male C57BL/6 mice by dorsal subcutaneous injec-
tion of 5 and 3 ml of air at day 0 and day 3, respectively. At day 6, the air 
pouches were injected with 200 µl of PBS containing 10 pmol CXCL12, 
300 pmol HMGB1 (WT or 3S) or CXCL12 10 pmol+HMGB1 300 pmol 
(WT or 3S), or with 200 µl of PBS containing 0, 1, or 10 nmol HMGB1 
(WT or 3S). After 6 h, cells were collected from the air pouches, stained 
with anti-Ly6C (BD) and anti-CD11b (BioLegend) antibodies and analyzed 
by flow cytometry.
Animal experimentation was performed in Istituto Scientifico San Raffaele 
as approved by “Comitato Istituzionale per la Buona Sperimetazione Animale 
della Fondazione San Raffaele del Monte Tabor” on September 19, 2011.
Cells. The mouse 3T3 fibroblast cell line and the THP-1 human acute 
monocytic leukemia cell line were purchased from American Type Culture 
Collection and cultured in DME supplemented with 10% FBS, 2 mM gluta-
mine, 100 U/ml penicillin, and 100 µg/ml streptomycin. PBMCs were 
isolated from buffy coats of donor blood (Hospital of Magenta, Milan, Italy) 
by Ficoll gradient centrifugation (Lymphoprep; AXIS-SHIELD). CD14+ 
monocytes were isolated by positive immunoselection (CD14 Microbeads; 
Miltenyi Biotec) according to the manufacturer’s instructions, and differenti-
ated into macrophages using X-Vivo medium supplemented with 1% heat 
inactivated human serum, GM-CSF, and M-CSF.
Production of recombinant WT and mutant HMGB1 proteins. The 
WT HMGB1 used in the experiments is the rat protein, with no tags or ad-
ditional amino acids, expressed in Escherichia coli and purified to homogeneity 
as previously described (Knapp et al., 2004). The plasmid encoding WT 
HMGB1 was freshly transformed into protease-deficient E. coli strain BL21 
(Novagen) and incubated in 2-YT medium. Protein expression was induced 
at 23°C by addition of 1 mM IPTG overnight. Harvested cells were resus-
pended in 50 mM Tris-HCl, pH 8.0, 20 mM EDTA, and 0.5 mM PMSF 
(containing or not containing 1 mM DTT, as appropriate) and sonicated at 
4°C. NaCl was added to a final concentration of 0.5 M, and the cell debris 
was discarded. Crystalline ammonium sulfate (0.39 g per ml) was added to 
the supernatant, and the protein precipitate was discarded. The supernatant 
was purified on a HiLoad 26/10 Phenyl Sepharose High Performance 
column (GE Healthcare) connected to a FPLC system (Akta Purifier; GE 
Healthcare). Proteins were eluted at room temperature by a continuous descend-
ing gradient of ammonium sulfate (39 to 0%) in 20 mM Hepes pH 7.9, 0.2 mM 
PMSF, 0.2 mM EDTA pH 8.0 (plus 0.5 mM DTT where appropriate). Fractions 
containing HMGB1 (identified by Coomassie staining after SDS-PAGE) 
were pooled, dialyzed overnight against 50 mM Hepes, pH 7.9, 0.2 mM 
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Student’s t or Mann-Whitney U tests; P values <0.05 were considered statis-
tically significant. For experiments with multiple doses and air pouch experi-
ments, ANOVA was performed, followed by Dunnett’s posttest.
Online supplemental material. Fig. S1 is a summary of HMGB1 
redox status versus activity. Fig. S2 shows the redox status of intracellular and 
extracellular HMGB1 in THP-1 cells. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20120189/DC1.
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